Cancer cell · 2021
Seroconversion rates following COVID-19 vaccination among patients with cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Thakkar Astha, Gonzalez-Lugo Jesus D, Goradia Niyati, Gali Radhika, Shapiro Lauren C, Pradhan Kith, Rahman Shafia, Kim So Yeon, Ko Brian, Sica R Alejandro, Kornblum Noah, Bachier-Rodriguez Lizamarie, McCort Margaret, Goel Sanjay, Perez-Soler Roman, Packer Stuart, Sparano Joseph, Gartrell Benjamin, Makower Della, Goldstein Yitz D, Wolgast Lucia, Verma Amit, Halmos Balazs
Аннотация
As COVID-19 adversely affects patients with cancer, prophylactic strategies are critically needed. Using a validated antibody assay against SARS-CoV-2 spike protein, we determined a high seroconversion rate (94%) in 200 patients with cancer in New York City that had received full dosing with one of the FDA-approved COVID-19 vaccines. On comparison with solid tumors (98%), a significantly lower rate of seroconversion was observed in patients with hematologic malignancies (85%), particularly recipients following highly immunosuppressive therapies such as anti-CD20 therapies (70%) and stem cell transplantation (73%). Patients receiving immune checkpoint inhibitor therapy (97%) or hormonal therapies (100%) demonstrated high seroconversion post vaccination. Patients with prior COVID-19 infection demonstrated higher anti-spike IgG titers post vaccination. Relatively lower IgG titers were observed following vaccination with the adenoviral than with mRNA-based vaccines. These data demonstrate generally high immunogenicity of COVID-19 vaccination in oncology patients and identify immunosuppressed cohorts that need novel vaccination or passive immunization strategies.